← board
ARQT
Arcutis Biotherapeutics, Inc.distress 0/10 · well-funded / low risk$27.29-2%today-13% from 52w high
Immunology / Inflammation 2
Lead: Psoriasis · est. market ~$30B (approx, global)
Revenue
$105M
Liquidity
$35M
Runway
—
Shares 1y
+4%
Price & events
+2.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-1.6%
1W
+3.9%
1M
+19.4%
3M
+4.2%
6M
+83.0%
1Y
+167.5%
2Y
+11.9%
5Y
-4.0%
All
Overview
- Market Cap
- $3.41B
- Enterprise Value
- $3.48B
- Volume
- 74.30K
- 52 Week Range
- $14.12 – $31.20
- Total Shares
- 125.08M
- Float Shares
- 92.38M
- Short %
- 11.96%
- % Held by Insiders
- 1.79%
- % Held by Institutions
- 110.07%
- RVOL
- 0.04x
- Beta
- 1.48
Pipeline stages · 1 programs
ARQ-154 Foam 0.3%
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-04-30 | Phase 1 | ARQ-154 Foam 0.3% | Psoriasis | 22 | completed |
| 2025-12-04 | Phase 2 | ARQ-151 cream 0.05% | Atopic Dermatitis (Eczema) | 101 | completed |
Catalyst news & presentations · 1
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $35 (+27% upside) · 8 analysts
- 2026-05-07NeedhamBuy
- 2026-03-02MizuhoOutperform
- 2026-02-27GuggenheimBuy
- 2026-02-26HC Wainwright & Co.Buy
- 2026-02-26TD CowenBuy
- 2026-02-26NeedhamBuy
Competitors — Psoriasis
- ABBVAbbVie Inc.$451.1B · D2
- AMGNAMGEN INC$195.4B · D3
- TKPHFTAKEDA PHARMACEUTICAL CO LTD$53.7B · D1
- PTGXProtagonist Therapeutics, Inc$8.6B · D0
- ORKAOruka Therapeutics, Inc.$5.5B · D5
- RCUSArcus Biosciences, Inc.$3.8B · D5
- VNDAVanda Pharmaceuticals Inc.$319M · D5
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- VYNEVYNE Therapeutics Inc.$29M · D5
- ALMSALUMIS INC.— · D4
Recent news
- 2026-07-23Arcutis: Intense Competition, Costs, Slow Growth Merit Downgrade To Hold (NASDAQ:ARQT) - Seeking Alpha
- 2026-07-23Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup - ChartMill
- 2026-07-23Enterprise value to revenue forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
- 2026-07-23Understanding Momentum Shifts in (ARQT) - Stock Traders Daily
- 2026-07-22Loss-Making Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Set To Breakeven - 富途牛牛
- 2026-07-21Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet - Yahoo Finance
- 2026-07-20Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum - ChartMill
- 2026-07-18Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,730 common shares worth $127,269.30 - Bitget
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.